Market Overview

DUSA Pharma Says Positive Results in Phase 2 Actinic

Share:

DUSA Pharmaceuticals, Inc.^® (Nasdaq: DUSA), a dermatology company that is developing and marketing its Levulan^® (aminolevulinic acid HCl) Photodynamic Therapy (PDT) platform, today announced results of an investigational study designed to examine and compare the safety and efficacy of broad area application of the Levulan^® Kerastick^® with or without occlusive dressing (where the treatment area is covered or wrapped) in conjunction with the BLU-U^® for the treatment of minimally to moderately thick actinic keratoses (AKs) on the upper extremities. The study showed a statistically significant lesion reduction and complete clearance of actinic keratoses of the extremities (hands and arms) when compared to treatment with vehicle.  The use of occlusion resulted in a statistically significant improvement in lesion clearance rates compared to treatment without occlusion. The study utilized the Levulan^® Kerastick^® (aminolevulinic acid HCl) for Topical Solution, 20% with the BLU-U^® Blue Light Photodynamic Therapy Illuminator which is FDA approved for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp. 

 

Related Articles (DUSA)

View Comments and Join the Discussion!

Posted-In: News FDA

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com